Divalproex Sodium
Product Images NDC 0615-8377

7 FDA label images from Ncs Healthcare Of Ky, Llc Dba Vangard Labs · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0615-8377). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 1)

Image 1 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 1)
Chemical structure of divalproex sodium shown as the repeated unit with sodium ion (Na+) associated, illustrating the molecular form of the active ingredient.*
FDA Label Image

Image 2 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 2)

Image 2 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 2)
A line chart comparing the percentage reduction in CPS rate between Divalproex Sodium Delayed-Release and placebo across a patient population. The vertical axis shows percentage reduction in CPS rate, from -100% to 100%, and the horizontal axis shows percentage of patients from 0 to 100%. Two lines represent treatment effects, illustrating improvements and worsening outcomes over the patient sample.*
FDA Label Image

Image 3 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 3)

Image 3 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 3)
A line graph depicting the percent reduction in CPS (complex partial seizure) rate on the vertical axis and the percent of patients on the horizontal axis. It compares high dose Divalproex Sodium Delayed Release and low dose Divalproex Sodium Delayed Release by showing two curves, one solid and one dashed, representing different dose responses. The vertical axis is annotated with improvement and worsening directions.*
FDA Label Image

Image 4 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 4)

Image 4 (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 4)
A bar chart comparing values between Placebo and Divalproex Sodium Extended-Release Tablets. The y-axis ranges from 0.0 to 1.2, with Placebo at 0.6 and Divalproex Sodium Extended-Release Tablets at 1.2. The chart includes a notation indicating a statistical value (p=0.006).*
FDA Label Image

Principal Display Panel (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 5)

Principal Display Panel (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 5)
Label for Divalproex Sodium Extended-Release Tablets, USP 250 mg, by NCS HealthCare of KY, LLC dba Vangard Labs. The label shows a package quantity of 30 tablets. Manufactured by Lupin and packaged by Vangard in Glasgow, KY. Includes multiple barcodes, lot number 8376, and storage instructions at 25°C with permitted excursions. Marked for institutional use only.*
FDA Label Image

Principal Display Panel (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 6)

Principal Display Panel (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 6)
This label is for Divalproex Sodium Extended-Release Tablets, USP 500 mg, provided by NCS HealthCare of KY, LLC dba Vangard Labs and manufactured by Lupin. The label indicates a quantity of 30 tablets and includes multiple barcode strips and lot number 8377. The packaging also notes storage conditions and is marked for institutional use only.*
FDA Label Image

Divalproex Sodium Er Tab 500mg Unit Dose Label (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 7)

Divalproex Sodium Er Tab 500mg Unit Dose Label (Divalproex Sodium Er Tabs 250 mg 8376 500 mg 8377 7)
Labels for Divalproex Sodium ER Tablets USP 500 mg show the product name, strength, formulation (extended-release tablets), and packaging information, including barcode and lot/expiration placeholders. The labels indicate packaging by Vangard, Glasgow, KY, and mention repackaging by Vanguard Labs. The main label includes dosage instructions, storage conditions, quantity of 30 tablets, and a statement that each ER tablet contains divalproex sodium equivalent to 500 mg valproic acid.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.